Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
05/03Samsung BioLogics' shares slide again; unit's valuation jump questioned
RE
05/02NOVARTIS : Gets Second FDA Approval for CAR-T Cancer Drug
DJ
05/01GILEAD SCIENCES : Quarterly Results Miss Wall Street Expectations -- Earnings Re..
DJ
04/26GILEAD SCIENCES : The Million Dollar Cancer Treatment No One Knows How to Pay fo..
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10Prisons Expand Hepatitis Treatment -- WSJ
DJ
03/09More Prison Inmates Get Access to Hepatitis-C Drugs
DJ
02/22SANGAMO THERAPEUTICS : Surges on Therapy Collaboration Deal with Kite -- Market ..
DJ
02/22Sangamo in $3 billion gene-editing deal with Gilead
RE
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08FTSE slides after BOE meeting as pound pops higher
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
02/07GlaxoSmithKline sees light at end of Advair tunnel
RE
02/06GILEAD SCIENCES : Reports Quarterly Loss Driven by Tax Charge -- Earnings Review
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 37,2x
Capi. / Sales 2019 19,8x
Capitalization 3 498 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147
ALNYLAM PHARMACEUTICALS, INC.-15.41%10 803
QIAGEN19.95%8 564
NEKTAR THERAPEUTICS-19.98%8 191
EXACT SCIENCES CORPORATION21.36%7 772
SAGE THERAPEUTICS INC2.06%7 686
ICON PLC23.36%7 442
ALKERMES PLC-19.11%6 864
PRA HEALTH SCIENCES INC9.76%6 272
BIO-TECHNE CORP18.35%5 753
IONIS PHARMACEUTICALS INC-9.36%5 679
CHARLES RIVER LABORATORIES INTL. INC7.18%5 621
FIBROGEN INC34.81%5 433
UNITED THERAPEUTICS CORPORATION-16.09%5 432
GALAPAGOS9.34%5 180
FOUNDATION MEDICINE INC100.44%5 063